Branded pharma’s revenue model is under siege—and it’s not just one problem. It’s a stack.
In a recent DrugPatentWatch post, the argument is blunt: the “branded” playbook—launch a blockbuster, ride exclusivity, defend share, repeat—has been getting sys…

Generic drug competition isn’t “first to file.” It’s “first to understand.”
If you’ve ever wondered how some generic manufacturers seem to move faster than the rest—turning FDA approvals into market share while competitors are still waiting on clarity—…

Biopharma hiring is broken in a very specific way: we keep treating IP as a “legal function” instead of an operating system.
That’s the agitation. Here’s the problem underneath it: when companies build IP portfolios, they don’t just file patents—they e…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Drug companies don’t just “get patents.” They build ecosystems.
That’s the core takeaway from a recent DrugPatentWatch deep dive on how innovators—and their legal teams—create patent thickets around biologic blockbusters, and what it would take to di…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most pharma deals don’t fail because the science is wrong. They fail because the legal risk was underestimated—often until it’s too late to unwind a transaction.
That’s why “prior a…

Most teams look at drug patents the wrong way.
They search for “the patent” that blocks a competitor—then they wait for the litigation calendar to tell them what’s possible. But formulation patents don’t work like that. They’re often the last mile of…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Pharma pipelines don’t fail because of science. They fail because of patents.
That’s the uncomfortable truth behind most “surprise” launch delays, licensing scramble, and last-minute redesigns. The root cause is rarely a lack of effort—it’s a lack of f…

Beyond the ANDA: How the 505(b)(2) Pathway Can Create Real Differentiation—and Real Defense
The generic playbook is familiar: file an ANDA, win on bioequivalence, and compete on price. But in today’s crowded therapeutic categories, “me-too” is a strate…